全文获取类型
收费全文 | 19465篇 |
免费 | 936篇 |
国内免费 | 103篇 |
专业分类
耳鼻咽喉 | 197篇 |
儿科学 | 290篇 |
妇产科学 | 266篇 |
基础医学 | 2665篇 |
口腔科学 | 382篇 |
临床医学 | 1422篇 |
内科学 | 5323篇 |
皮肤病学 | 287篇 |
神经病学 | 1484篇 |
特种医学 | 766篇 |
外科学 | 2869篇 |
综合类 | 82篇 |
一般理论 | 2篇 |
预防医学 | 511篇 |
眼科学 | 367篇 |
药学 | 1505篇 |
中国医学 | 88篇 |
肿瘤学 | 1998篇 |
出版年
2023年 | 94篇 |
2022年 | 178篇 |
2021年 | 328篇 |
2020年 | 150篇 |
2019年 | 252篇 |
2018年 | 299篇 |
2017年 | 230篇 |
2016年 | 299篇 |
2015年 | 330篇 |
2014年 | 430篇 |
2013年 | 521篇 |
2012年 | 880篇 |
2011年 | 930篇 |
2010年 | 537篇 |
2009年 | 451篇 |
2008年 | 798篇 |
2007年 | 858篇 |
2006年 | 836篇 |
2005年 | 907篇 |
2004年 | 818篇 |
2003年 | 798篇 |
2002年 | 802篇 |
2001年 | 698篇 |
2000年 | 745篇 |
1999年 | 665篇 |
1998年 | 243篇 |
1997年 | 202篇 |
1996年 | 222篇 |
1995年 | 171篇 |
1994年 | 173篇 |
1993年 | 134篇 |
1992年 | 519篇 |
1991年 | 517篇 |
1990年 | 480篇 |
1989年 | 456篇 |
1988年 | 366篇 |
1987年 | 328篇 |
1986年 | 354篇 |
1985年 | 331篇 |
1984年 | 231篇 |
1983年 | 194篇 |
1982年 | 103篇 |
1980年 | 100篇 |
1979年 | 175篇 |
1978年 | 118篇 |
1977年 | 111篇 |
1974年 | 99篇 |
1972年 | 106篇 |
1969年 | 97篇 |
1968年 | 100篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test 总被引:2,自引:0,他引:2
A vital component of chemotherapy is selecting effective anticancer agents for the patient and determining an appropriate dose and administration regimen. Prediction of the drug sensitivity of each patient and cell kill kinetics of the drug may improve the outcome of treatment and avoid unnecessary dosing of the drug. For this reason, the development and clinical application of anticancer drug sensitivity tests and cell kill kinetics tests which successfully reflect clinical outcomes are required. In the present study, we tried to establish a cell kill kinetics test through the use of new anticancer agents: paclitaxel, docetaxel, SN-38, vinorelbine, and gemcitabine. These agents were studied at concentrations close to their clinical doses using a collagen gel droplet embedded-culture drug sensitivity test (CD-DST). It is thought that the mechanism, by which the anticancer agents used in this study exert their effects is dependent on the cell cycle; however, the cell kill kinetics of these agents at clinical concentrations has not yet been clarified in vitro. We investigated the drug sensitivity and cell kill kinetics of these new anticancer agents against a human colon cancer strain. Results of this study suggest that the test method established by us can predict drug sensitivity and cell kill kinetics of the agents, and can be a useful tool in deciding appropriate treatment regimen for individual patients. 相似文献
992.
In situ production of estrogens in human breast carcinoma 总被引:3,自引:0,他引:3
Suzuki T Moriya T Ishida T Kimura M Ohuchi N Sasano H 《Breast cancer (Tokyo, Japan)》2002,9(4):296-302
Recent studies have demonstrated that biologically active estrogens are locally produced from circulating inactive steroids in the estrogen-dependent breast carcinoma. The in situ production of estrogens in the breast carcinoma is considered to play an important role in the proliferation of breast cancer cells, especially in the postmenopausal women. Therefore, the total blockade of this pathway may inhibit estrogenic actions in breast cancer tissues and lead to an improvement in the prognosis in these patients. In this review, we describe the recent studies concerning the expression of enzymes related to intratumoral estrogen production, including aromatase, 17beta-hydroxysteroid dehydrogenase, steroid sulfatase, and estrogen sulfotransferase in human breast carcinoma tissues, and discuss the biological significance of local production of estrogens in human breast cancer. 相似文献
993.
Watanabe O Haga S Shimizu T Imamura H Kinoshita J Utada Y Okabe T Kimura K Hirano A Kajiwara T Aiba M 《International journal of clinical oncology / Japan Society of Clinical Oncology》2002,7(5):0322-0325
Intravenous digital subtraction angiography (IV-DSA) was performed before and after neoadjuvant chemotherapy (NACT) in five
patients with locally advanced breast cancer, and the efficacy of NACT was evaluated on the basis of the results of IV-DSA
and histopathological examination. Following NACT, the maximum density of tumor enhancement (MAX) in the IV-DSA image decreased
by 61.6% in case 1, 50% in case 2, 58.1% in case 3, 90.8% in case 4, and 97.2% in case 5. In all five patients, the efficacy
of chemotherapy was rated as a partial response in terms of tumor size, while histological efficacy was rated as slightly
effective in cases 1–4 and moderately effective in case 5. The pathological efficacy of NACT was highest in case 5, which
showed the greatest decrease in MAX. These results indicate that variations in MAX reflect clinical efficacy, and, to some
extent, also permit prediction of pathological efficacy.
Received: March 4, 2002 / Accepted: June 10, 2002
Correspondence to:O. Watanabe 相似文献
994.
Lee CM Tanaka T Murai T Kondo M Kimura J Su W Kitagawa T Ito T Matsuda H Miyasaka M 《Cancer research》2002,62(15):4282-4288
An increased level of chondroitin sulfate (CS) expression on the cell surface is often associated with malignant transformation and the progression of tumor cells. In this study, CSs expressed on highly metastatic tumor cells were used as a target for the selective delivery of anticancer drugs by polyethylene glycol (PEG)-coated liposomes that contained a new cationic lipid 3,5-dipentadecycloxybenzamidine hydrochloride (TRX-20). We found that PEG-coated TRX-20 liposomes (TRX-20 liposomes) bound preferentially to certain CSs, such as CS B, CS D, and CS E, whereas PEG-coated liposomes lacking TRX-20 showed no significant binding to any of the glycosaminoglycans tested. In vitro, TRX-20 liposomes, but not plain PEG liposomes, avidly bound to and were readily internalized by highly metastatic tumor cells such as LM8G5 and ACHN cells, which express large amounts of CS on the cell surface. When TRX-20 liposomes were loaded with cisplatin, they effectively killed the CS-expressing tumor cells in vitro, whereas cisplatin-PEG liposomes lacking TRX-20 were totally ineffective. When injected systemically, TRX-20 liposomes preferentially accumulated in the liver and in solid s.c. LM8G5 tumors. Therapeutic experiments in mice bearing a s.c. LM8G5 tumor revealed that cisplatin-loaded TRX-20 liposomes were significantly more effective in reducing the local tumor growth than cisplatin-loaded plain PEG liposomes or free cisplatin. Furthermore, the cisplatin-loaded TRX-20 liposomes markedly suppressed metastatic spreading of LM8G5 tumor cells to the liver, significantly increasing the survival time of the tumor-bearing mice. These results demonstrate that the CS-targeted delivery of anticancer drugs by novel cationic liposomes represents a potentially useful strategy to prevent the local growth and metastasis, particularly to the liver, of tumor cells that have enhanced expression of CS. 相似文献
995.
Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer 总被引:9,自引:0,他引:9
996.
Kimura Y Kikkawa N Iijima S Kato T Naoi Y Hayashi T Tanigawa T Yamamoto H Kurokawa E 《Gan to kagaku ryoho. Cancer & chemotherapy》2002,29(8):1403-1409
It has been reported that the response rate to TS-1 of advanced recurrent gastric cancer was the highest rate (46.5%) of effectiveness among anti-cancer agents, but the incidence of adverse reactions to this drug has been found to be as high as 83.2%, with grade 3 or severer reactions occurring in 20.3% of patients. Taking into consideration the post-marketing survey finding that adverse reactions to the drug first appear 2-3 weeks after the start of oral TS-1 therapy, we attempted a new dosing regimen for this drug, wherein each session of therapy lasted for 2 weeks, with a one-week interval between two consecutive sessions (herein-after called "the 2-week regimen"). This regimen was employed based on the expectation that the adverse reactions to the drug would be minimized and that the consecutive dosing period could be prolonged, while keeping the anti-cancer potency at a level similar to that expected with the 4-week dosing regimen with a 2-week interval between sessions (the 4-week regimen). The subjects were 38 patients with advanced or recurrent stomach cancer who were treated with TS-1 at our center between September 1999 and November 2001. Twenty-four patients treated using the 4-week method until January 2001 were taken as a historical control, and compared with 14 patients treated using the 2-week method from February 2001 and afterwards. The incidence of adverse reactions was 71% in the 2-week regimen group against 92% in the 4-week regimen group. The incidence of grade 3 or severe adverse reactions was 8% in the 2-week group and 21% in the 4-week group. Thus, the incidence of adverse reactions was lower in the 2-week group. The percentage of patients who complied with the dosing instructions completely during a 6-month period, as evaluated by the Kaplan-Meier method, was 86% in the 2-week group and 58% in the 4-week group. The response rate, as calculated in patients whose lesions could be evaluated, was 25% in the 2-week group and 19% in the 4-week group. These results suggest that the 2-week regimen may allow safer outpatient drug therapy using TS-1 and merits a trial when considering the QOL of patients. We propose conducting a phase-II multi-center clinical study of this regimen in the near future. 相似文献
997.
Sasaki T Nakamura K Toba T Kimura M Ohga S Urashima Y Terashima H Masuda K 《Gan to kagaku ryoho. Cancer & chemotherapy》2002,29(8):1417-1420
A 61-year-old male patient had esophageal carcinoma with multiple mediastinal and right supraclavicular lymph node metastases. Chemotherapy consisting of infusion of nedaplatin and continuous infusion of 5-fluorouracil was performed. After three courses of the chemotherapy, the patient was treated with a combination of cisplatin and 5-FU and radiotherapy. However, only radiotherapy was performed after 18 Gy because of grade 3 leukocytonenia during the chemoradiotherapy. The patient achieved a partial response (nearly complete response) for 9 months after the initiation of the treatment. In conclusion, chemotherapy with NDP and 5-FU followed by chemoradiotherapy is effective and safe for patients with esophageal carcinoma with multiple lymph node metastases. 相似文献
998.
Ikeda T Jinno H Matsui A Mitsui Y Asaga S Muto T Wada M Kitajima M 《Gan to kagaku ryoho. Cancer & chemotherapy》2002,29(9):1509-1515
Adjuvant chemo-endocrine therapy for breast cancer (ACETBC) trial has been the first large scaled clinical trial performed in Japan. Several prospective randomized trials have been performed in Japan since ACETBC-1 trial started in 1985. The effect of oral 5-FU agents had been tested in prospective randomized trials and the statistically marginal effect of oral 5-FU agents in adjuvant settings has been reported. Several trials having CMF as a control arm started in 1996 when CMF combination chemotherapy was approved by the government. The results of these trials have not been published. To perform good clinical trials, it is imperative to construct infrastructures including clinical research coordinator, and abolish governmental regulation of the dose of anticancer agents. 相似文献
999.
beta-Catenin alteration in cancer of the ampulla of Vater 总被引:2,自引:0,他引:2
Kawakami M Kimura Y Furuhata T Zenbutsu H Yanai Y Mukaiya M Satoh Y Murata S Hirata K 《Journal of experimental & clinical cancer research : CR》2002,21(1):23-27
To investigate the contribution of beta-catenin to the development of carcinoma of the ampulla of Vater, genetic alterations of beta-catenin gene, CTNNB-1 were searched. Mutational analysis of exon3 in CTNNB-1, which encodes the serine/threonine residues for GSK-3beta phosphorylation sites, was performed on 21 cases of carcinoma of the ampulla of Vater, by means of polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) followed by nucleotide sequencing. We found one deleted mutation at codon 32 to approximately 65 in one case of carcinoma of the ampulla of Vater. We also analyzed subcellular localization of beta-catenin protein in all cases immunohistochemically, and confirmed its accumulation in the nucleus in four cases including in a CTNNB-1 mutated one. This is the first study to show CTNNB-1 mutation and beta-catenin expression in carcinoma of the ampulla of Vater. These results suggested that abnormal Wnt-wingless signaling and in particular beta-catenin alteration caused accumulation of beta-catenin, which might partially contribute to the development of carcinoma of the ampulla of Vater. 相似文献
1000.
Pulmonary alveolar proteinosis as a terminal complication in myelodysplastic syndromes: a report of four cases detected on autopsy 总被引:1,自引:0,他引:1
Shoji N Ito Y Kimura Y Nishimaki J Kuriyama Y Tauchi T Yaguchi M Payzulla D Ebihara Y Ohyashiki K 《Leukemia research》2002,26(6):591-595
Secondary pulmonary alveolar proteinosis (PAP) is one of the complications of hematologic malignancy and immunosuppressive diseases. We encountered four cases of myelodysplastic syndrome (MDS) associated with PAP detected on autopsy. They consisted of two refractory anemia (RA) and two patients with refractory anemia with excess blasts in transformation (RAEBt) at the time of MDS diagnosis, but all of them developed leukemic phase and were resistant to chemotherapy at the time of pulmonary episodes. Of the four MDS patients, two also had pulmonary aspergillosis. Previously, 69 patients with PAP associated with hematologic disorders have been reported, but there have been only seven cases with MDS, including our four patients. Of the 69 reported cases of PAP in hematologic malignancies, 24/63 (38%) informative patients with infection had fungal infections of the lung; 2/7 (29%) MDS cases had fungal infection. We should, therefore, pay careful attention to this possibility in cases of MDS with lung complications, including PAP, especially in patients in the leukemic phase of MDS. 相似文献